SE327779B - - Google Patents
Info
- Publication number
- SE327779B SE327779B SE04365/62A SE436562A SE327779B SE 327779 B SE327779 B SE 327779B SE 04365/62 A SE04365/62 A SE 04365/62A SE 436562 A SE436562 A SE 436562A SE 327779 B SE327779 B SE 327779B
- Authority
- SE
- Sweden
- Prior art keywords
- amino
- plasmin
- acid
- amino acid
- millimole
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4826—Trypsin (3.4.21.4) Chymotrypsin (3.4.21.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6435—Plasmin (3.4.21.7), i.e. fibrinolysin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
A plasmin preparation for therapeutic use comprises plasmin and, as stabilizer and solubilizer therefor, 0.002 millimole to 1 millimole of amino acid per unit of plasmin. The amino acid may be an aliphatic amino monocarboxylic acid, preferably an amino acid having at least one amino group bound to a carbon atom which is separated from the carboxylic group or groups by at least one carbon atom, or it may be a dipeplide such as glycyl glycine and leucyl glycine. Typical amino acids are lysine, e -aminocaproic acid, L-arginine, g -aminobutyric acid, ornithine and a -N-acetyl-L-arginine.ALSO:A plasmin preparation for therapeutic use comprises plasmin and, as stabilizer and solubilizer therefor, 0,002 millimole to 1 millimole of amino acid per unit of plasmin. The amino acid may be an aliphatic amino-monocarboxylic acid and it is preferred that the amino acid is one having at least one amino group bound to a carbon atom which is separated from the carboxylic group or groups by at least one carbon atom; it may also be a dipeptide. Typical, amino acids are lysine, e -amino-caproic acid, L-arginine, g -aminobutyric acid, ornithine, glycyl glycine and leucyl glycine. The plasmin may be dissolved in an aqueous injectable liquid at pH 2 to 3, the amino acid added, the pH adjusted to 7, the mixture filtered and freeze dried.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DK169161AA DK98833C (en) | 1961-04-25 | 1961-04-25 | Method for stabilizing therapeutically useful plasmin solutions. |
Publications (1)
Publication Number | Publication Date |
---|---|
SE327779B true SE327779B (en) | 1970-08-31 |
Family
ID=8107240
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SE04365/62A SE327779B (en) | 1961-04-25 | 1962-04-18 |
Country Status (9)
Country | Link |
---|---|
BE (1) | BE616779A (en) |
CH (1) | CH456848A (en) |
DK (1) | DK98833C (en) |
FI (1) | FI43764B (en) |
FR (1) | FR2140M (en) |
GB (1) | GB985498A (en) |
NL (1) | NL147634B (en) |
NO (1) | NO123024B (en) |
SE (1) | SE327779B (en) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2750159C3 (en) * | 1977-11-09 | 1980-05-22 | Lentia Gmbh, Chem. U. Pharm. Erzeugnisse - Industriebedarf, 8000 Muenchen | Infusion solution for the treatment of hepatic encephalopathy and a process for the manufacture thereof |
JPH0672105B2 (en) * | 1985-10-02 | 1994-09-14 | 持田製薬株式会社 | Thrombolytic agent and manufacturing method thereof |
US4777043A (en) * | 1985-12-17 | 1988-10-11 | Genentech, Inc. | Stabilized human tissue plasminogen activator compositions |
US7544500B2 (en) | 1999-11-13 | 2009-06-09 | Talecris Biotherapeutics, Inc. | Process for the production of a reversibly inactive acidified plasmin composition |
US6355243B1 (en) † | 1999-11-13 | 2002-03-12 | Bayer Corporation | Method of thrombolysis by local delivery of active plasmin |
EP1545588A4 (en) * | 2002-07-23 | 2007-12-05 | Ludwig Inst Cancer Res | Methods and compositions for activating or inhibiting vegf-d and vegf-c |
GB0228409D0 (en) | 2002-12-06 | 2003-01-08 | Thromb X Nv | Pharmacological vitreolysis |
US20060257391A1 (en) * | 2005-05-11 | 2006-11-16 | Bausch & Lomb Incorporated | Non-surgical method for preventing or reducing the rate of the progression of non-proliferative diabetic retinopathy and the treatment of other ocular conditions |
BRPI0913397B8 (en) | 2008-06-04 | 2021-05-25 | Grifols Therapeutics Inc | method for preparing plasmin |
JP5789521B2 (en) | 2009-03-03 | 2015-10-07 | グリフオルス・セラピユーテイクス・インコーポレーテツドGrifols Therapeutics,Inc. | Compositions, methods and kits for producing plasminogen; and plasmin produced therefrom |
CN106167797B (en) * | 2016-07-28 | 2019-04-09 | 国药集团武汉血液制品有限公司 | The lyophilized preparation and preparation method thereof of human fibrin dissolution proenzyme |
-
1961
- 1961-04-25 DK DK169161AA patent/DK98833C/en active
-
1962
- 1962-04-16 NO NO144057A patent/NO123024B/no unknown
- 1962-04-18 SE SE04365/62A patent/SE327779B/xx unknown
- 1962-04-19 GB GB15352/62A patent/GB985498A/en not_active Expired
- 1962-04-24 BE BE616779A patent/BE616779A/en unknown
- 1962-04-25 CH CH497562A patent/CH456848A/en unknown
- 1962-04-25 NL NL62277635A patent/NL147634B/en not_active IP Right Cessation
- 1962-04-25 FI FI0828/62A patent/FI43764B/fi active
- 1962-07-20 FR FR904689A patent/FR2140M/en not_active Expired
Also Published As
Publication number | Publication date |
---|---|
CH456848A (en) | 1968-05-31 |
FR2140M (en) | 1963-11-12 |
GB985498A (en) | 1965-03-10 |
NO123024B (en) | 1971-09-20 |
DK98833C (en) | 1964-05-25 |
FI43764B (en) | 1971-03-01 |
BE616779A (en) | 1962-10-24 |
NL147634B (en) | 1975-11-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Vigneaud et al. | The synthesis of an octapeptide amide with the hormonal activity of oxytocin | |
SE327779B (en) | ||
RO80806A (en) | PROCEDURE FOR ENZYMATIC OBTAINING PEPTIDES | |
NO911787D0 (en) | PEPTIDAMINES AND PROCEDURES FOR PREPARING THEREOF. | |
JPS5692850A (en) | Acylpeptide* its manufacture and medicinal medicine containing it | |
EA200300678A1 (en) | PEPTIDES AND / OR PROTEINS, AND ALSO THEIR APPLICATION FOR THE OBTAINING OF THERAPEUTIC AND / OR PREVENTIVE PHARMACEUTICAL COMPOSITION | |
KR840008279A (en) | Atomization Method of Amino Acid-Containing Fat Emulsion | |
Thomas et al. | Indications of spatial relations among structures recognizing amino acids and Na+ at a transport receptor site | |
DK151884D0 (en) | POLYPEPTIDES | |
GB1364991A (en) | Process for the preparation of oligopeptide derivatives | |
ES2053589T3 (en) | NEW CYSTINE COMPOUNDS, THEIR MANUFACTURE AND USE. | |
GB1354584A (en) | Clear liquid laxative-antacid composition | |
IL43056A (en) | Peptides having acth activity containing alpha-aminooxy carboxylic acids on both terminal groups and a process for the preparation thereof | |
ATE86974T1 (en) | (2-CYAN-2-OXIMINOACETYL)AMINO ACID DERIVATIVES. | |
GB1046523A (en) | New preparations with adrenocorticotropic hormone activity and the manufacture thereof | |
ATE87906T1 (en) | (2-CYAN-2-OXIMINOACETYL)AMINO ACID DERIVATIVES. | |
GB866423A (en) | Improvements in or relating to chymotrypsin solutions | |
GB1129774A (en) | Tubing fluid for storing sutures | |
DE60141632D1 (en) | COMPOSITION FOR STABILIZING FAT-SOLUBLE VITAMINS IN AQUEOUS SOLUTION | |
FR2013179A1 (en) | Polypeptide derivatives | |
GB848406A (en) | Novel tripeptide and tetrapeptide derivatives | |
GB1343152A (en) | Process for the manufacture of peptides | |
GB1190077A (en) | Peptides and Process for Preparing them | |
ES416516A1 (en) | A procedure for the preparation of nonapeptides. (Machine-translation by Google Translate, not legally binding) | |
FR2185416A1 (en) | Isotonic injectable ACTH compsns - with low content of polyphloretin phosphate, but with prolonged activity |